On 21 March 2018, orphan designation (EU/3/18/1997) was granted by the European Commission to QRC Consultants Ltd, United Kingdom, for miransertib for the treatment of Proteus syndrome.
The sponsorship was transferred to QRC Ireland, Ireland, in September 2018.
The sponsorship was transferred to Merck Sharp & Dohme B.V., Netherlands in December 2020.
|Disease / condition||
Treatment of Proteus syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.